Download full-text PDF |
Source |
---|
J Clin Med
December 2024
Department of Pharmacy, CHOC Children's Hospital, Orange, CA 92868, USA.
: Cannabinoid Hyperemesis Syndrome (CHS), associated with long-term cannabinoid use, has been increasingly observed in emergency room visits as more states in the U.S. have legislatively permitted medical and recreational marijuana use.
View Article and Find Full Text PDFJ Psychopharmacol
January 2025
Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Objective: Therapeutic drug monitoring (TDM) indicators have been suggested to predict overall outcome responses to olanzapine (OLZ) treatments in terms of efficacy and metabolic syndrome. This study aimed to investigate whether paraoxonase-1 (PON-1) activity can be used to predict schizophrenia patient outcomes.
Methods: Schizophrenic patients ( = 50) aged between 20 and 65 years who received OLZ treatment were recruited, and their Positive and Negative Syndrome Scale scores, PON-1 activity, and olanzapine drug levels normalized by dose (OLZ/D) and its metabolite N-desmethyl-olanzapine (DMO), together with biochemical parameters, were determined.
Actas Dermosifiliogr
November 2024
Trichology Unit, Grupo de Dermatología Pedro Jaén, Madrid, Spain; Servicio de Dermatología, Hospital Universitario Ramón y Cajal, Departamento de Biología de Sistemas, Facultad de Medicina, Universidad de Alcalá, IRYCIS, Madrid, Spain.
Trichotillomania (TTM) is an obsessive-compulsive disorder in which affected individuals recurrently pull-out hair from any region of the body, causing hair loss or alopecia. The management of TTM is a therapeutic challenge for dermatologists and consists of a combination of pharmacological and non-pharmacological alternatives. Cognitive-behavioral therapy has successfully been used to treat TTM.
View Article and Find Full Text PDFOlanzapine is an antipsychotic medication that is used in the management of schizophrenia and bipolar disorder, but it is not without any adverse effects. We present the following case of a 24-year-old man with a history of schizoaffective disorder, obesity, and anxiety, who developed hypertriglyceridemia-induced acute pancreatitis after six months on olanzapine. Despite his adherence to the medication, routine metabolic monitoring was not performed leading to a delayed diagnosis of hypertriglyceridemia and subsequent complications.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!